BioMarin Pharmaceuticals BMRN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.24B+0.7% | $3.22B+4.1% | $3.09B+1.0% | $3.06B+3.8% | $2.95B+3.4% | ||
| $760.88M+6.1% | $717.44M+24.2% | $577.87M-7.7% | $626.24M+3.2% | $606.61M+4.5% | ||
| $2.48B-0.9% | $2.5B-0.5% | $2.52B+3.2% | $2.44B+4.0% | $2.34B+3.1% | ||
| 76.5%-1.2pp | 77.7%-3.6pp | 81.3%+1.8pp | 79.6%+0.1pp | 79.4%-0.2pp | ||
| $942M+2.2% | $921.93M+2.1% | $903.03M+33.1% | $678.45M-3.2% | $700.93M-6.2% | ||
| $1.21B+4.5% | $1.15B+18.5% | $973.42M+1.6% | $958.48M-3.1% | $989.24M-2.0% | ||
| $2.93B+4.1% | $2.81B+13.4% | $2.48B+8.3% | $2.29B-1.8% | $2.33B-1.7% | ||
| —— | —— | $615.5M-20.7% | $776.08M+25.2% | $619.65M+28.0% | ||
| $22.99M+111% | $10.9M+1.9% | $10.7M-3.5% | $11.09M-7.5% | $11.98M-5.4% | ||
| —— | —— | —— | —— | —— | ||
| $412.75M-19.0% | $509.63M-25.0% | $679.27M-19.1% | $840.04M+24.6% | $674.31M+24.5% | ||
| $116.85M-12.5% | $133.58M-15.9% | $158.86M-13.1% | $182.8M+21.5% | $150.42M+30.9% | ||
| —— | —— | $520.42M-20.8% | $657.24M+25.5% | $523.88M+22.7% | ||
| —— | —— | $2.67-21.0% | $3.38+25.2% | $2.70+22.2% | ||
| $436.51M-18.6% | $536.42M-23.2% | $698.22M-18.7% | $859.33M+20.9% | $710.79M+22.4% | ||
| 13.5%-3.2pp | 16.7%-5.9pp | 22.6%-5.5pp | 28%+4.0pp | 24.1%+3.7pp | ||
| $362.61M-20.6% | $456.87M-25.8% | $615.5M-20.7% | $776.08M+25.2% | $619.65M+28.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioMarin Pharmaceuticals's revenue?
- BioMarin Pharmaceuticals (BMRN) generated $3.2B in revenue over the trailing twelve months, up 9.9% year over year.
- Is BioMarin Pharmaceuticals profitable?
- BioMarin Pharmaceuticals reported $501.0M in net income over the trailing twelve months, a 16.8% net margin.
- What are BioMarin Pharmaceuticals's profit margins?
- Gross margin is 76.5% and operating margin is 19.9%, with a 16.8% net margin.
- What is BioMarin Pharmaceuticals's earnings per share?
- BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $2.56.
- Where does BioMarin Pharmaceuticals's income statement data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
